Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNEL 1.5/30 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Treatment of acne vulgaris (for women ≥15 years who have reached menarche and desire an oral contraceptive)
Prevention of pregnancy
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Hepatic: ethinyl estradiol primarily via CYP3A4; norethindrone via reduction, sulfate and glucuronide conjugation. First-pass metabolism extensive. Enterohepatic recirculation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
EE: ~97% bound to albumin; NET: ~61% bound to albumin, ~36% bound to SHBG.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
EE: ~6.5 L/kg; NET: ~4 L/kg. Reflects extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
EE: ~40-45% (oral); NET: ~64% (oral) due to first-pass metabolism.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in acute hepatic disease, hepatic adenomas, or history of cholestatic jaundice with prior oral contraceptive use. For Child-Pugh A (mild impairment), no adjustment; for Child-Pugh B or C (moderate to severe), contraindicated.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy not established in pediatric patients; use only after menarche and as per adult dosing if post-menarche.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women. No dose adjustment necessary if used in women over 40 years who are premenopausal and not at increased risk of cardiovascular disease; however, consider lower dose formulations for women over 35 who smoke or have other risk factors.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially >35 years) and with smoking intensity. Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic disorders (DVT, PE, stroke, MI), especially in smokers >35 years. Hepatic neoplasia, gallbladder disease, hypertension, carbohydrate and lipid effects. Use caution with prediabetes/diabetes, migraine, SLE, hereditary angioedema. Discontinue if jaundice, visual disturbances, or suspected pregnancy. Do not use before menarche.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders (current or history), cerebrovascular or coronary artery disease, known or suspected breast cancer or other estrogen-sensitive neoplasia, undiagnosed abnormal genital bleeding, pregnancy, known or suspected pregnancy, liver tumors (benign or malignant) or active liver disease, age >35 years and smoking, hypersensitivity to any component.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food interactions require restriction. Grapefruit juice may slightly increase ethinyl estradiol levels, but not clinically significant. Avoid St. John's Wort as it may reduce contraceptive efficacy.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
FDA Pregnancy Category X. Postmarketing studies have not identified an increased risk of major birth defects or miscarriages with combined hormonal contraceptives (CHCs) prior to pregnancy or inadvertently during early pregnancy. However, CHCs are contraindicated during pregnancy because they provide no benefit and may cause fetal harm. First trimester: No increased risk of congenital anomalies from inadvertent use. Second and third trimesters: Administration during pregnancy has been associated with an increased risk of adverse outcomes including hepatotoxicity (jaundice, cholestasis), estrogen-induced fetal masculinization of female genitalia, and potential long-term effects from androgen exposure. Use is contraindicated once pregnancy is confirmed.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk. Estrogen-containing CHCs may reduce milk production and composition, particularly in the early postpartum period. The milk-to-plasma (M/P) ratio is approximately 0.6 for norethindrone and 0.01 for ethinyl estradiol. Use is not recommended during breastfeeding; progestin-only contraceptives are preferred alternatives.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dosing adjustments apply as Junel 1.5/30 is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (increased hepatic metabolism, volume of distribution, renal clearance) would theoretically require dose adjustments, but the product is not indicated for use during pregnancy.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Junel 1.5/30 is a monophasic oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for contraception. The pill-free interval during the placebo week may trigger withdrawal bleeding. Consistent timing is crucial; a delay of more than 3 hours in taking the active pill requires backup contraception for 7 days. Consider potential drug interactions with hepatic enzyme inducers (e.g., rifampin, carbamazepine) that may reduce efficacy. Monitor blood pressure and liver function periodically.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time, starting on the first day of your menstrual period.,If you miss a pill, follow the package insert instructions: if missed for less than 12 hours, take it immediately and continue; if missed for more than 12 hours, take the last missed pill and use backup contraception for 7 days.,Common side effects include nausea, breast tenderness, and spotting, especially in the first few months.,Smoking increases the risk of serious cardiovascular side effects, especially in women over 35 years old.,If you experience severe headache, chest pain, leg pain, or vision changes, seek medical attention immediately.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNEL 1.5/30 vs ALYACEN 1/35, answered by our medical review team.
JUNEL 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNEL 1.5/30 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNEL 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNEL 1.5/30 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNEL 1.5/30 is classified as Category C. FDA Pregnancy Category X. Postmarketing studies have not identified an increased risk of major birth defects or miscarriages with combined hormonal contraceptives (CHCs) prior to p. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.